Reports Q4 revenue $58.6M, consensus $56.6M. “We delivered strong fourth quarter performance amidst a challenging macro-economic environment. Our teams navigated well while executing our business strategy, and we took actions to ensure that we remain an agile organization,” said Dr. Wenbin Jiang, CEO of Cytek Bioscience. “As we look ahead to 2024, we remain laser focused on effectively driving strategic growth and delivering long-term profitability. Cytek remains on the forefront of innovation and industry leadership, and we are excited for the large opportunities ahead.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTKB:
- Cytek Biosciences Enhances Executive Severance Benefit Plan
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
- Cytek Biosciences signs agreement with CRG, UPF to accelerate discoveries
